| Project/Area Number |
13671038
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
NOBUHARA Kenji Kansai Medical University, Faculty of Medicine, Assistant Professor, 医学部, 講師 (90247932)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KINOSHITA Toshihiko Kansai Medical University, Faculty of Medicine, Professor, 医学部, 教授 (20186290)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2002: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2001: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
|---|
| Keywords | Alzheimer Disease / SPECT / rCBF / Donepezil |
|---|
| Research Abstract |
The purpose of this study is to investigate the relation between the clinical efficacy and the changes of regional cerebral blood flow(rCBF) in the early stage of Alzheimer's disease(AD) patients after treatment of Donepezil Hydrochloride(DH). The subjects were seven outpatients. They were diagnosed to have AD on criteria of DSM-IV and NINCDS-ADRDA. The cognitive functions were estimated by ADAS-Jcog. A three-headed gamma-camera system(Toshiba GCA-9300A/DI) was used. In each measurement, 111 MBq[123I]-IMP was injected intravenously. The reconstruction was made with 64×64 matrix. CBF was calculated on a voxel-by-voxel basis using the ARG method. In five of seven patients(the responders to DH) * scores of ADAS-Jcog were improved within three months after treatment of DH therapy. On the other hand, the two patients(the non-responder to DH therapy) had no significant changes. The responder showed increase of CBF in whole brain with more than 10% than baseline within three months after treatment. In this group, marked per fusion increase was found in basal ganglia. The non-responder showed reduction of CBF in whole brain with 10% more than baseline. SPECT is promising tool with which to assess the impact of DH therapy on brain functioning of AD patients.
|
